Methylone is a synthetic stimulant belonging to the cathinone family, a group of drugs chemically related to the stimulant found naturally in the khat plant. Often called bk-MDMA (beta-keto-MDMA), it is structurally almost identical to MDMA (ecstasy) but with one extra oxygen atom on its molecular backbone. That small chemical difference gives it a shorter, somewhat milder set of effects compared to MDMA, while introducing its own distinct risks. Methylone is a Schedule I controlled substance in the United States, meaning it has no accepted medical use and is illegal to manufacture, possess, or distribute.
Origins and Classification
Methylone was first synthesized in 1996 by chemists Peyton Jacob III and Alexander Shulgin, originally explored as a potential antidepressant and anti-Parkinson’s drug. It never made it through clinical development for either purpose. By the late 2000s, it had surfaced in the recreational drug market, frequently sold online as “bath salts” or mislabeled as MDMA in pressed pills and powders.
Chemically, methylone is a substituted cathinone, the same drug subclass that includes mephedrone and butylone. Its formal name is 1-(1,3-benzodioxol-5-yl)-2-(methylamino)propan-1-one. The DEA permanently placed methylone into Schedule I in April 2013, after an initial temporary ban. It carries the same legal penalties as heroin and LSD under federal law.
How It Works in the Brain
Methylone increases the activity of three key chemical messengers in the brain: dopamine, serotonin, and norepinephrine. It does this primarily by blocking the proteins (transporters) that normally recycle these chemicals back into nerve cells after they’ve been released. The result is a temporary flood of all three, which drives both its pleasurable and its dangerous effects.
Lab studies show methylone is most potent at blocking the norepinephrine transporter, followed closely by the dopamine transporter, with weaker activity at the serotonin transporter. This profile sits somewhere between a pure stimulant like methamphetamine (which hits dopamine hardest) and MDMA (which hits serotonin hardest). That balance explains why users describe feeling both energized and emotionally open, though with less intensity on the empathy side than MDMA typically produces.
Effects and Duration
When taken orally, methylone’s effects typically begin within 15 to 60 minutes and last 3 to 5 hours total, with peak effects around 60 to 90 minutes after ingestion. In a controlled human trial using a 200 mg dose, peak subjective effects hit about 45 minutes in, which is noticeably faster than MDMA’s typical one-hour onset.
The mood-related effects reported in that trial centered on three clusters: stimulation and wellbeing (feeling energized, euphoric, and “high”), altered perception (changes in how lights, distances, and surroundings look and feel), and empathy (feeling open, trusting, and wanting closeness with others). These subjective effects generally normalized within 2.5 to 3 hours, making the psychological experience considerably shorter than MDMA’s.
Physical effects are harder to shake off quickly. In the same trial, heart rate increased by an average of about 29 beats per minute above baseline, and that elevation remained significantly above placebo levels for a full 10 hours before returning to normal at 24 hours. Blood pressure rose as well. Interestingly, body temperature did not rise significantly compared to placebo in the controlled setting, though real-world use in hot environments with physical exertion (like dancing) tells a different story.
How Methylone Compares to MDMA
The comparison matters because methylone is frequently sold as MDMA, and people who think they’re taking ecstasy may actually be taking methylone. In head-to-head testing, a 200 mg dose of methylone produced subjective effects roughly comparable to a 100 mg dose of MDMA. Put simply, methylone is about half as potent by weight for producing feelings of euphoria, empathy, and stimulation.
The timeline also differs. Methylone kicks in faster, peaks sooner, and wears off more quickly. Someone expecting the longer arc of an MDMA experience might redose, thinking the drug isn’t working, which increases the risk of taking too much. The cardiovascular strain from methylone also persists far longer than the psychological high, meaning a person can feel sober while their heart is still under significant stress.
Serious Health Risks
The most dangerous acute risk from methylone is hyperthermia, a dangerously high body temperature. While controlled lab conditions showed minimal temperature changes, real-world settings involving heat exposure, dehydration, and sustained physical activity can push body temperature to life-threatening levels. Severe hyperthermia can trigger a cascade of organ damage: metabolic acidosis (the blood becoming too acidic), breakdown of muscle tissue that clogs the kidneys, widespread abnormal blood clotting, coma, and death.
Serotonin syndrome is another serious concern. This occurs when serotonin levels in the brain become dangerously high, causing a recognizable set of symptoms: rapid heart rate, profuse sweating, dilated pupils, muscle rigidity, exaggerated reflexes, and involuntary muscle jerking (clonus). In documented cases, patients have presented with all of these signs along with an inability to stand, significant metabolic acidosis, and early signs of kidney and liver stress. The risk of serotonin syndrome climbs sharply if methylone is combined with antidepressants, other serotonin-active drugs, or additional doses of stimulants.
Other commonly reported adverse effects include anxiety, agitation, tremors, seizures, and vomiting.
How the Body Breaks It Down
Methylone is processed primarily by a liver enzyme called CYP2D6, with smaller contributions from a few other liver enzymes. This is notable because roughly 5 to 10 percent of people of European descent are “poor metabolizers” who have a less active version of CYP2D6. For these individuals, methylone clears from the body more slowly, potentially intensifying and prolonging its effects at the same dose.
The same enzyme, CYP2D6, is responsible for processing MDMA and a wide range of common medications, including certain antidepressants and beta-blockers. Taking methylone alongside other substances that compete for this enzyme can slow the metabolism of both, raising blood levels unpredictably.
Typical Doses Reported by Users
Self-reported dosing data from user communities places a low dose below 100 mg, a moderate dose between 100 and 200 mg, and anything above 200 mg as a high dose. These numbers carry no guarantee of safety. Because methylone is manufactured in unregulated labs, the actual content of any given sample is unpredictable, and pills or powders sold as methylone may contain other substances entirely. The mismatch between the short psychological effects (2.5 to 3 hours) and the prolonged cardiovascular effects (up to 10 hours) makes redosing particularly risky, even within what users consider a “moderate” range.